MedTrace Logo

Statins for Prevention of Contrast Induced Nephropathy

NCT00770796 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2015-10-16

No results posted yet for this study

Summary

In this randomized study the investigators wish to explore the role of pre-procedural statin therapy for the prevention of contrast induced nephropathy in patients with moderate-to-severe renal dysfunction, submitted to elective coronary or angioplasty.

Conditions

  • Contrast Induced Nephropathy

Interventions

DRUG

Atorvastatin

80 mg die

DRUG

Placebo

Sponsors & Collaborators

  • Ospedale Misericordia e Dolce

    lead OTHER

Principal Investigators

  • Mauro Maioli, MD · Ospedale Misericordia e Dolce, Prato

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-03-31
Completion
2008-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770796 on ClinicalTrials.gov